Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.

Breast Cancer (Auckl) · 2011 · PMC3201097 · PMID 22084574

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.1200

boldest claim

The sentences

showed a trendP = 0.07so close (0.05 < p ≤ 0.1)

Analysis of the data by original therapy assignment showed a trend toward improvement in 4-year DFS after treatment with exemestane compared with placebo (relative risk [RR] = 0.68; P = 0.07).

also in 53,322 other papers

a nonsignificant trendP = 0.08so close (0.05 < p ≤ 0.1)

21 There was a nonsignificant trend toward improvement in overall survival with exemestane compared with tamoxifen (HR = 0.85; P = 0.08).

also in 5,406 other papers

did not reach statistical significanceP = 0.12not close (p > 0.1)

The risk of a DFS event favored exemestane but did not reach statistical significance (HR = 0.89; P = 0.12).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.